{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T20:31:20Z","timestamp":1771101080929,"version":"3.50.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T00:00:00Z","timestamp":1603238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T00:00:00Z","timestamp":1603238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital, Linkou","doi-asserted-by":"crossref","award":["CIRPG3H0061~2 and CORPG3J0151~2"],"award-info":[{"award-number":["CIRPG3H0061~2 and CORPG3J0151~2"]}],"id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005795","name":"Chang Gung Memorial Hospital, Linkou","doi-asserted-by":"crossref","award":["CMRPG3I0451, CMRPG3J0971~3, CRRPG3K0021~2, CMRPG3K0601 and NMRPG3K6201~3"],"award-info":[{"award-number":["CMRPG3I0451, CMRPG3J0971~3, CRRPG3K0021~2, CMRPG3K0601 and NMRPG3K6201~3"]}],"id":[{"id":"10.13039\/501100005795","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>The association between immune-related adverse events (irAEs) and survival outcomes in patients with advanced melanoma receiving therapy with immune checkpoint inhibitors (ICIs) has not been well established, particularly in Asian melanoma.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>We retrospectively reviewed 49 melanoma patients undergoing therapy with ICIs (anti-PD-1 monotherapy), and analyzed the correlation between irAEs and clinical outcomes including progression-free survival (PFS) and overall survival (OS). Results: Overall, the patients who experienced grade 1\u20132 irAEs had longer PFS (median PFS, 4.6 vs. 2.5\u2009months; HR, 0.52; 95% CI: 0.27\u20130.98; <jats:italic>p<\/jats:italic>\u2009=\u20090.042) and OS (median OS, 15.2 vs. 5.7\u2009months; HR, 0.50; 95% CI: 0.24\u20131.02; <jats:italic>p<\/jats:italic>\u2009=\u20090.058) than the patients who did not experience irAEs. Regarding the type of irAE, the patients with either skin\/vitiligo or endocrine irAEs showed better PFS (median PFS, 6.1 vs. 2.7\u2009months; HR, 0.40, 95% CI: 0.21\u20130.74; <jats:italic>p<\/jats:italic>\u2009=\u20090.003) and OS (median OS, 18.7 vs. 4.5\u2009months; HR, 0.34, 95% CI: 0.17\u20130.69, p\u2009=\u20090.003) than patients without any of these irAEs.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Melanoma patients undergoing anti-PD-1 monotherapy and experiencing mild-to-moderate irAEs (grade 1\u20132), particularly skin (vitiligo)\/endocrine irAEs had favorable survival outcomes. Therefore, the association between irAEs and the clinical outcomes in melanoma patients undergoing anti-PD-1 ICIs may be severity and type dependent.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12885-020-07508-7","type":"journal-article","created":{"date-parts":[[2020,10,21]],"date-time":"2020-10-21T12:02:53Z","timestamp":1603281773000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["The association between immune-related adverse events and survival outcomes in Asian patients with advanced melanoma receiving anti-PD-1 antibodies"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1081-8805","authenticated-orcid":false,"given":"Chiao-En","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chan-Keng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng-Ting","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pei-Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ching-Fu","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kun-Yun","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Bing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Liang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao-Wei","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I-Wen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng-Tao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shir-Hwa","family":"Ueng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gigin","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Fen","family":"Lin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Yuan","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John Wen-Cheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,21]]},"reference":[{"issue":"8","key":"7508_CR1","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711\u201323.","journal-title":"N Engl J Med"},{"issue":"11","key":"7508_CR2","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","volume":"19","author":"FS Hodi","year":"2018","unstructured":"Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Cowey CL, Lao CD, Schadendorf D, Wagstaff J, Dummer R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19(11):1480\u201392.","journal-title":"Lancet Oncol"},{"issue":"4","key":"7508_CR3","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1093\/annonc\/mdz011","volume":"30","author":"O Hamid","year":"2019","unstructured":"Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph R, Weber JS, et al. Five-year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE-001. Ann Oncol. 2019;30(4):582\u20138.","journal-title":"Ann Oncol"},{"issue":"16","key":"7508_CR4","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, et al. Five-year survival with combined Nivolumab and Ipilimumab in advanced melanoma. N Engl J Med. 2019;381(16):1535\u201346.","journal-title":"N Engl J Med"},{"issue":"14","key":"7508_CR5","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","volume":"377","author":"JD Wolchok","year":"2017","unstructured":"Wolchok JD, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D, Ferrucci PF, et al. Overall survival with combined Nivolumab and Ipilimumab in advanced melanoma. N Engl J Med. 2017;377(14):1345\u201356.","journal-title":"N Engl J Med"},{"issue":"11","key":"7508_CR6","doi-asserted-by":"publisher","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","volume":"17","author":"FS Hodi","year":"2016","unstructured":"Hodi FS, Chesney J, Pavlick AC, Robert C, Grossmann KF, McDermott DF, Linette GP, Meyer N, Giguere JK, Agarwala SS, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016;17(11):1558\u201368.","journal-title":"Lancet Oncol"},{"issue":"11","key":"7508_CR7","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1200\/JCO.18.01998","volume":"37","author":"C Lebbe","year":"2019","unstructured":"Lebbe C, Meyer N, Mortier L, Marquez-Rodas I, Robert C, Rutkowski P, Menzies AM, Eigentler T, Ascierto PA, Smylie M, et al. Evaluation of two dosing regimens for Nivolumab in combination with Ipilimumab in patients with advanced melanoma: results from the phase IIIb\/IV CheckMate 511 trial. J Clin Oncol. 2019;37(11):867\u201375.","journal-title":"J Clin Oncol"},{"issue":"1","key":"7508_CR8","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s40425-019-0805-8","volume":"7","author":"S Das","year":"2019","unstructured":"Das S, Johnson DB. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J Immunother Cancer. 2019;7(1):306.","journal-title":"J Immunother Cancer"},{"issue":"1","key":"7508_CR9","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.clinthera.2018.11.004","volume":"41","author":"N Okada","year":"2019","unstructured":"Okada N, Kawazoe H, Takechi K, Matsudate Y, Utsunomiya R, Zamami Y, Goda M, Imanishi M, Chuma M, Hidaka N, et al. Association between immune-related adverse events and clinical efficacy in patients with melanoma treated with Nivolumab: a multicenter retrospective study. Clin Ther. 2019;41(1):59\u201367.","journal-title":"Clin Ther"},{"key":"7508_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ejca.2018.10.014","volume":"109","author":"J Rogado","year":"2019","unstructured":"Rogado J, Sanchez-Torres JM, Romero-Laorden N, Ballesteros AI, Pacheco-Barcia V, Ramos-Levi A, Arranz R, Lorenzo A, Gullon P, Donnay O, et al. Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients. Eur J Cancer. 2019;109:21\u20137.","journal-title":"Eur J Cancer"},{"key":"7508_CR11","doi-asserted-by":"publisher","unstructured":"Riudavets M, Barba A, Maroto P, Sullivan IG, Anguera G, Paez D. Correlation between immune-related adverse events (irAEs) and efficacy in patients with solid tumors treated with immune-checkpoints inhibitors (ICIs). J Clin Oncol. 2018;36(15). https:\/\/doi.org\/10.1200\/JCO.2018.36.15_suppl.3064.","DOI":"10.1200\/JCO.2018.36.15_suppl.3064"},{"key":"7508_CR12","doi-asserted-by":"publisher","unstructured":"Elias R, Yan F, Singla N, Levonyack N, Formella J, Christie A, Kapur P, Bowman AI, Hammers HJ, Hannan R, et al. Immune-related adverse events are associated with improved outcomes in ICI-treated renal cell carcinoma patients. J Clin Oncol. 2019;37(7). https:\/\/doi.org\/10.1200\/JCO.2019.37.7_suppl.645.","DOI":"10.1200\/JCO.2019.37.7_suppl.645"},{"issue":"3","key":"7508_CR13","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.cllc.2018.10.002","volume":"20","author":"M Grangeon","year":"2019","unstructured":"Grangeon M, Tomasini P, Chaleat S, Jeanson A, Souquet-Bressand M, Khobta N, Bermudez J, Trigui Y, Greillier L, Blanchon M, et al. Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in non-small-cell lung Cancer. Clinical Lung Cancer. 2019;20(3):201\u20137.","journal-title":"Clinical Lung Cancer"},{"key":"7508_CR14","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.lungcan.2017.11.019","volume":"115","author":"K Sato","year":"2018","unstructured":"Sato K, Akamatsu H, Murakami E, Sasaki S, Kanai K, Hayata A, Tokudome N, Akamatsu K, Koh Y, Ueda H, et al. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. Lung Cancer. 2018;115:71\u20134.","journal-title":"Lung Cancer"},{"key":"7508_CR15","doi-asserted-by":"crossref","unstructured":"Maher VE, Fernandes LL, Weinstock C, Tang SH, Agarwal S, Brave M, Ning YM, Singh H, Suzman D, Xu J et al: Analysis of the Association Between Adverse Events and Outcome in Patients Receiving a Programmed Death Protein 1 or Programmed Death Ligand 1 Antibody. J Clin Oncol 2019, 37(30):2730.","DOI":"10.1200\/JCO.19.00318"},{"issue":"2","key":"7508_CR16","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1007\/s00432-018-2819-x","volume":"145","author":"A Indini","year":"2019","unstructured":"Indini A, Di Guardo L, Cimminiello C, Prisciandaro M, Randon G, De Braud F, Del Vecchio M. Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma. J Cancer Res Clin Oncol. 2019;145(2):511\u201321.","journal-title":"J Cancer Res Clin Oncol"},{"key":"7508_CR17","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1200\/EDBK_200643","volume":"38","author":"E Borcoman","year":"2018","unstructured":"Borcoman E, Nandikolla A, Long G, Goel S, Le Tourneau C. Patterns of response and progression to immunotherapy. Am Soc Clin Oncol Educ Book. 2018;38:169\u201378.","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"7","key":"7508_CR18","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","volume":"35","author":"JS Weber","year":"2017","unstructured":"Weber JS, Hodi FS, Wolchok JD, Topalian SL, Schadendorf D, Larkin J, Sznol M, Long GV, Li H, Waxman IM, et al. Safety profile of Nivolumab Monotherapy: a pooled analysis of patients with advanced melanoma. J Clin Oncol. 2017;35(7):785\u201392.","journal-title":"J Clin Oncol"},{"issue":"5","key":"7508_CR19","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1634\/theoncologist.2019-0674","volume":"25","author":"A Suo","year":"2020","unstructured":"Suo A, Chan Y, Beaulieu C, Kong S, Cheung WY, Monzon JG, Smylie M, Walker J, Morris D, Cheng T. Anti-PD1-induced immune-related adverse events and survival outcomes in advanced melanoma. Oncologist. 2020;25(5):438\u201346.","journal-title":"Oncologist"},{"key":"7508_CR20","doi-asserted-by":"publisher","unstructured":"Wu CE, Yang CK, Peng MT, Huang PW, Lin YF, Cheng CY, Chang YY, Chen HW, Hsieh JJ, Chang JW. Immune Checkpoint Inhibitors for Advanced Melanoma: Experience at a Single Institution in Taiwan. Front Oncol. 2020. https:\/\/doi.org\/10.3389\/fonc.2020.00905.","DOI":"10.3389\/fonc.2020.00905"},{"key":"7508_CR21","doi-asserted-by":"crossref","unstructured":"Haanen J, Carbonnel F, Robert C, Kerr KM, Peters S, Larkin J, Jordan K, Committee EG: Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018, 29(Suppl 4):iv264-iv266.","DOI":"10.1093\/annonc\/mdy162"},{"issue":"1","key":"7508_CR22","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12916-020-01549-2","volume":"18","author":"X Zhou","year":"2020","unstructured":"Zhou X, Yao Z, Yang H, Liang N, Zhang X, Zhang F. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis. BMC Med. 2020;18(1):87.","journal-title":"BMC Med"},{"key":"7508_CR23","doi-asserted-by":"crossref","unstructured":"Bai X, Quach H, Cann CG, Zhang M, Kim MS, Kasumova GG, Si L, Tang B, Cui C, Yang X: Heterogeneous response and irAE patterns in advanced melanoma patients treated with anti-PD-1 monotherapy from different ethnic groups: Subtype distribution discrepancy and beyond. In.: American Society of Clinical Oncology; 2020.","DOI":"10.1200\/JCO.2020.38.15_suppl.10020"},{"issue":"11","key":"7508_CR24","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1016\/j.bulcan.2018.07.005","volume":"105","author":"T Passat","year":"2018","unstructured":"Passat T, Touchefeu Y, Gervois N, Jarry A, Bossard C, Bennouna J. Physiopathological mechanisms of immune-related adverse events induced by anti-CTLA-4, anti-PD-1 and anti-PD-L1 antibodies in cancer treatment. B Cancer. 2018;105(11):1033\u201341.","journal-title":"B Cancer"},{"issue":"6","key":"7508_CR25","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1001\/jamaoncol.2019.0046","volume":"5","author":"HT Quach","year":"2019","unstructured":"Quach HT, Dewan AK, Davis EJ, Ancell KK, Fan R, Ye F, Johnson DB. Association of Anti-Programmed Cell Death 1 cutaneous toxic effects with outcomes in patients with advanced melanoma. Jama Oncol. 2019;5(6):906\u20138.","journal-title":"Jama Oncol"},{"issue":"28","key":"7508_CR26","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","volume":"36","author":"KC Arbour","year":"2018","unstructured":"Arbour KC, Mezquita L, Long N, Rizvi H, Auclin E, Ni A, Martinez-Bernal G, Ferrara R, Lai WV, Hendriks LEL, et al. Impact of baseline steroids on efficacy of programmed cell Death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung Cancer. J Clin Oncol. 2018;36(28):2872\u20138.","journal-title":"J Clin Oncol"},{"key":"7508_CR27","doi-asserted-by":"publisher","unstructured":"Mian I, Yang M, Zhao H, Shah M, Diab A, Shannon V, Patel A, Amaria RN, Giordano SH, Suarez-Almazor ME: Immune-related adverse events and survival in elderly patients with melanoma treated with ipilimumab. J Clin Oncol. 2016;34(15). https:\/\/doi.org\/10.1200\/JCO.2016.34.15_suppl.3047.","DOI":"10.1200\/JCO.2016.34.15_suppl.3047"},{"issue":"11","key":"7508_CR28","doi-asserted-by":"publisher","first-page":"1206","DOI":"10.1001\/jamadermatol.2015.1916","volume":"151","author":"M Sanlorenzo","year":"2015","unstructured":"Sanlorenzo M, Vujic I, Daud A, Algazi A, Gubens M, Luna SA, Lin K, Quaglino P, Rappersberger K, Ortiz-Urda S. Pembrolizumab cutaneous adverse events and their association with disease progression. Jama Dermatology. 2015;151(11):1206\u201312.","journal-title":"Jama Dermatology"},{"key":"7508_CR29","doi-asserted-by":"crossref","unstructured":"Yamazaki N, Takahashi A, Namikawa K, Takenouchi T, Nakamura Y, Kitano S, Fujita T, Kubota K, Yamanaka T, Kawakami Y. Response of nivolumab monotherapy in 124 Japanese patients with advanced melanoma: interim analysis of prospective observational study (CREATIVE study). Ann Oncol. 2019;30.","DOI":"10.1093\/annonc\/mdz429.001"},{"issue":"1","key":"7508_CR30","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.jdermsci.2017.10.009","volume":"89","author":"Y Fujisawa","year":"2018","unstructured":"Fujisawa Y, Yoshino K, Otsuka A, Funakoshi T, Uchi H, Fujimura T, Matsushita S, Hata H, Okuhira H, Tanaka R, et al. Retrospective study of advanced melanoma patients treated with ipilimumab after nivolumab: analysis of 60 Japanese patients. J Dermatol Sci. 2018;89(1):60\u20136.","journal-title":"J Dermatol Sci"},{"key":"7508_CR31","doi-asserted-by":"publisher","unstructured":"Gomes-Lima CJ, Kwagvan J, King F, Fernandez SJ, Burman KD, Veytsman I: A comprehensive meta-analysis of endocrine immune-related adverse events of immune checkpoint inhibitors and outcomes in head and neck cancer and lung cancer. J Clin Oncol. 2019;37(15). https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.e14096.","DOI":"10.1200\/JCO.2019.37.15_suppl.e14096"},{"issue":"7","key":"7508_CR32","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","volume":"33","author":"HE Teulings","year":"2015","unstructured":"Teulings HE, Limpens J, Jansen SN, Zwinderman AH, Reitsma JB, Spuls PI, Luiten RM. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. J Clin Oncol. 2015;33(7):773\u201381.","journal-title":"J Clin Oncol"},{"issue":"19","key":"7508_CR33","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, et al. Adjuvant Pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789\u2013801.","journal-title":"N Engl J Med"},{"key":"7508_CR34","doi-asserted-by":"crossref","unstructured":"Eggermont AMM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Khattak A, Carlino MS, et al. Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive Pembrolizumab or placebo: a secondary analysis of a randomized clinical trial. Jama Oncol. 2020.","DOI":"10.1001\/jamaoncol.2019.5570"},{"issue":"1","key":"7508_CR35","doi-asserted-by":"publisher","first-page":"1673635","DOI":"10.1080\/2162402X.2019.1673635","volume":"9","author":"Y Ma","year":"2020","unstructured":"Ma Y, Yang H, Kroemer G. Endogenous and exogenous glucocorticoids abolish the efficacy of immune-dependent cancer therapies. Oncoimmunology. 2020;9(1):1673635.","journal-title":"Oncoimmunology"},{"issue":"23","key":"7508_CR36","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1200\/JCO.2013.49.5283","volume":"31","author":"A Giobbie-Hurder","year":"2013","unstructured":"Giobbie-Hurder A, Gelber RD, Regan MM. Challenges of guarantee-time bias. J Clin Oncol. 2013;31(23):2963\u20139.","journal-title":"J Clin Oncol"},{"key":"7508_CR37","doi-asserted-by":"crossref","unstructured":"Schadendorf D, Wolchok JD, Hodi FS, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob JJ, Cowey CL, Lao CD, Chesney J et al: Efficacy and Safety Outcomes in Patients With Advanced Melanoma Who Discontinued Treatment With Nivolumab and Ipilimumab Because of Adverse Events: A Pooled Analysis of Randomized Phase II and III Trials. J Clin Oncol 2017, 35(34):3807.","DOI":"10.1200\/JCO.2017.73.2289"},{"issue":"44","key":"7508_CR38","doi-asserted-by":"publisher","first-page":"22246","DOI":"10.1073\/pnas.1908079116","volume":"116","author":"SA Tahir","year":"2019","unstructured":"Tahir SA, Gao J, Miura Y, Blando J, Tidwell RSS, Zhao H, Subudhi SK, Tawbi H, Keung E, Wargo J, et al. Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities. Proc Natl Acad Sci U S A. 2019;116(44):22246\u201351.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"7508_CR39","doi-asserted-by":"crossref","unstructured":"Boland P, Pavlick AC, Weber J, Sandigursky S: Immunotherapy to treat malignancy in patients with pre-existing autoimmunity. J Immunother Cancer. 2020;8(1):e000356.","DOI":"10.1136\/jitc-2019-000356"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07508-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-07508-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07508-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,20]],"date-time":"2021-10-20T23:26:05Z","timestamp":1634772365000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07508-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,21]]},"references-count":39,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["7508"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07508-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,21]]},"assertion":[{"value":"1 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the institutional review board (IRB) of CGMH (202000182B0). The consent to participate was not required because of retrospective entity of this study which was approved by IRB of CGMH.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None declared.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1018"}}